CEO/Founder of RUPPERT U.S. IP GmbH & U.S. Patent Attorney
Dr. Siegfried Ruppert practices in the area of U.S. intellectual property law and focuses on patent prosecution and opinion work - primarily in the biotech area. Among others, Dr. Ruppert assists corporate and institutional clients in all areas of life sciences and biotechnology with securing patent rights in the United States and abroad and managing their patent portfolios.
After more than 28 years of scientific research and legal work in the United States, Dr. Ruppert returned to his roots in Heidelberg, Germany, where he founded RUPPERT U.S. IP GmbH (www.us-patente.com; in preparation). Prior to founding RUPPERT U.S. IP GmbH, he held various positions at several U.S.-based law firms (Taylor English Duma LLP, Duane Morris LLP, Townsend and Townsend and Crew LLP (now Kilpatrick Townsend & Stockton LLP), and Flehr Hobach Test Albritton & Herbert LLP (now Dorsey & Whitney LLP)). Dr. Ruppert is admitted to practice at several courts in California. Since 1998 he is registered to practice before the United States Patent and Trademark Office.
Before entering the legal field, Dr. Ruppert held a Group Leader position at Genentech, Inc., where his team identified and characterized novel proteins of therapeutic interest. Prior to that, as a Postdoctoral Fellow, he performed scientific research at both the University of California, Berkeley, and the Ruprecht-Karls University of Heidelberg/German Cancer Research Center, Germany, where he designed, implemented and managed independent research projects focusing on mammalian gene regulation, transcription factors and cloning of several genes. Dr. Ruppert is an inventor on a number of U.S. patents, has co-authored nearly 40 scientific articles in peer-reviewed journals and published on legal U.S. patent-related issues.